Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone Add-on to Insulin in Type 2 Diabetes
NCT00329225Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2002
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by GSK. Primary endpoint: Glycated Hemoglobin A1c at 28 weeks. Started Sep 2002; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00329225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329225.